Skip to main content
Fig. 9 | Breast Cancer Research

Fig. 9

From: Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner

Fig. 9

Schematic diagram depicting the proposed signaling pathway involved in interferon-induced transmembrane protein 1 (IFITM1) upregulation in SUM149 cells. IFITM1 is one of the interferon-stimulated genes (ISGs) that are induced through the canonical Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway due to increased expression of interferon α (IFNα). The binding of IFNα to its receptor interferon (alpha, beta and omega) receptor (IFNAR1/2) leads to the induction of the canonical JAK-STAT pathway, which involves phosphorylation of STAT1, STAT2, and the formation of the complex interferon-stimulated gene factor 3 (ISGF3), ultimately inducing many ISGs, including IFITM1. In the nucleus, ISGF3 recruits chromatin remodeling complex brahma-related gene 1 (BRG1) via STAT2 to remodel the promoter and expose interferon-stimulated response element (ISRE)/interferon gamma-activated site (GAS) for transcription factor binding. Alternatively, STAT2 can homodimerize upon phosphorylation, and bind interferon regulatory factor 9 (IRF9) to form a non-ISGF3 complex that is capable of binding the GAS or ISRE/IRF sequences at the promoter region of a subset of ISGs and induce their transcription without the participation of STAT1 in a noncanonical interferon signaling pathway. The presence of both GAS and ISRE/IRF consensus sequences at the IFITM1 promoter suggests that its transcription can be induced by both canonical and noncanonical signaling pathways, resulting in its overexpression in SUM149 cells

Back to article page